Novel Evaluations of Aging and Gender-Affirming Hormone Therapy on Vascular Endothelial Function and Metabolic Profiles in Transgender Women Compared to Age Group-Matched Cisgender Adults
This study is examining how gender-affirming hormone therapy affects the health of blood vessels and impacts cardiovascular disease risk in transgender women.
Do you qualify?
• Transgender women (i.
e., assigned male at birth but identify as female) taking
estradiol and spironolactone
o Ages 18 to 40 or 50 to 75 years
o In good general health
o Have been on hormones for at least 1 year
o No history of gonadectomy
o No history of cancer, diabetes or heart disease
o Non-smoker (or quit at least one year ago)
Main Procedures Involved: • Blood tests for hormones, cholesterol, clotting factor and other labs • Blood vessel cell collection • Dietary analysis • Physical activity monitor • Questionnaires • Ultrasound of the blood vessels • Measurements of bone mineral density and body composition • Compensation provided
Sean Iwamoto, MD
Protocol Number: 18-2258
More information available at ClinicalTrials.gov: NCT04066283
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers